Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading single-gene form of autism spectrum disorder, encompassing cognitive, behavioral, and physical forms of clinical involvement. FXS is caused by large expansions of a noncoding CGG repeat (>200 repeats) in the FMR1 gene, at which point the gene is generally silenced. Absence of FMR1 protein (FMRP), important for synaptic development and maintenance, gives rise to the neurodevelopmental disorder. There is, at present, no therapeutic approach that directly reverses the loss of FMRP; however, there is an increasing number of potential treatments that target the pathways dysregulated in FXS, including those that address the enhanced activity of the mGluR5 pathway and deficits in GABA pathways. Based on studies of targeted therapeutics to date, the prospects are good for one or more effective therapies for FXS in the near future.

Original languageEnglish (US)
Pages (from-to)365-381
Number of pages17
JournalAnnual Review of Pharmacology and Toxicology
Volume62
DOIs
StatePublished - Jan 6 2022
Externally publishedYes

Keywords

  • FMR1
  • autism
  • CGG repeat
  • FMRP
  • FXAND

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint

Dive into the research topics of 'Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon'. Together they form a unique fingerprint.

Cite this